Prevalence of Malaria Parasitemia (MP) and Hepatitis B Surface Antigen (HBsAg) Co-Infection Among HIV/AIDS Patients, Jalingo, Taraba State

Page Numbers: 1-17
Published
2024-07-03
Digital Object Identifier: 10.58578/amjsai.v1i1.3294
Save this to:
Article Metrics:
Viewed : 5 times
Downloaded : 6 times
Article can trace at:

Author Fee:
Free Publication Fees for Foreign Researchers (0.00)

Please do not hesitate to contact us if you would like to obtain more information about the submission process or if you have further questions.


  • Akwa Vera Y. Taraba State University, Jalingo, Nigeria
  • Okonofua Eghe Patricia National Biotechnology Research and Development Agency, Jalingo, Nigeria
  • Ifraimu Daniel National Biotechnology Research and Development Agency, Jalingo, Nigeria
  • Bando Christopher David National Biotechnology Research and Development Agency, Jalingo, Nigeria
  • David Ephraim Haruna Plateau State University, Bokkos, Nigeria
  • Adamu Tutuwa Nashuka National Biotechnology Research and Development Agency, Jalingo, Nigeria

Abstract

Human Immunodeficiency Virus (HIV) cannot be called a particular diseases or infection, but it could rightly be referred to as a phenomenon or syndrome that breaks through the body defense mechanism gradually which exposes the body to all kind of diseases resulting in Acquired Immune Deficiency Syndrome (AIDS). This Study focused on the prevalence of malaria and Hepatitis B surface Antigen (HBsAg) in people living with HIV. The result of the study has revealed that out of 148 HIV patients attending clinic at government house clinic Jalingo, 114 (77%) tested positive for malaria and 13 tested positive to hepatitis B surface antigen (HBsAg) with a prevalence of 8.8%. An association between HIV and occupation was evaluated, high risk occupation, based on the exposure to associated risk factor (student, civil servants and business men) accounted for high prevalence of 75.6%, while low risk occupation (housewives and farmers) accounted for 24.5%. 91(61.4%) of the patients reside in the rural areas while 57(38.5%) reside in the urban area. It was observed that male of both rural and urban area within the age group of 26-30 and 41-45 years presented a higher prevalence of 39% and 18.2% respectively while patients of both rural and urban area within the age group of 0-5 and 11-15 years accounted for a lower incidence rate with only 2.4% and 4% respectively.

Keywords: HBsAg; Malaria parasitemia; HIV/AIDS; HBV

Citation Metrics:





How to Cite
Y., A. V., Patricia, O. E., Daniel, I., David, B. C., Haruna, D. E., & Nashuka, A. T. (2024). Prevalence of Malaria Parasitemia (MP) and Hepatitis B Surface Antigen (HBsAg) Co-Infection Among HIV/AIDS Patients, Jalingo, Taraba State. African Multidisciplinary Journal of Sciences and Artificial Intelligence, 1(1), 1-17. https://doi.org/10.58578/amjsai.v1i1.3294
Issue
Vol 1 No 1 (2024): African Multidisciplinary Journal of Sciences and Artificial Intelligence
Section
Articles

Creative Commons License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

References

Alter, M.J. (2006). Epidemiology of viral hepatitis and HIV co infection. J Hepatol. 44(1):S6-9.
Alvarez-Uria, G., Ratcliffe, L. and Vilar, J.F. (2009). Long term outcome of tenofovir-disproxil fumarate use against hepatitis B in an HIV-infecetd cohort. HIV Med. 10:269-73.
Bani-Sadr, F., Palmer, P., Scieux, C. and Molina, J.M. (2004). Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients’ co infected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis. 39:1062-4.
Bando, C. D., Tutuwa, A. J., Kefas, F., Jesse, S. P., Blessing Smart Aigbogun, S. B. and Garba, B. A. (2020). Prevalence of sickle cell disease/ABO blood group among secondary school students: A case study of government day secondary school (GDSS) mile six Jalingo, Taraba state, Nigeria. International Journal of Advanced Scientific Research. 5(6): 70-75.
Banhamou,Y., Bochet, M. and Martins. D. (2009). Liver fibrosis progression in HIV and HBV counteracted patients Hepatology, 30: 1044-1058.
Chung, B., et al., (2001); Human immune deficiency virus and Hepatitis B co-infection: pathogenic interaction, natural history and therapy. AIDS clinical Rev. 263-306
Dharmadhikari, C.A., Kullkarni, R.D., Udgaonkar, C. and Panlar, S.G. (2004). Incidence of hepatitis B surface antigen (HBSAg) in liver disease and voluntary blood donor. Journal of medical Association; 88(3): 73-75
Gashsau, A. (1991). Hepatitis B markers in Nigeria patients with primary liver cell carcinoma. Trop Geog. Med. 43:64-67.
Gerberging, J.L.(1999). Incidence and prevalence of Human Immunodeficiency virus, Hepatitis C and cytomegalo-vi rus among health personel at risk for blood exposure: final report from longitudinal study. The journal infectious diseases. 170-140-7.
Greenberg, A.E et al. (2005). Plasmodium facilparum malaria and perinally acquired Human Immnodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study children. N. Engl. Journal of Medical. 325(2): 105, 2005.
Greenberg, A.E, Reddymm, Dewar, R. and Henrard, D. (2004). Increase prevalence of severe malaria and primary acquired Human Immunodefiecency Virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N. Engl. Journal of Medical. 325(2): 105.
Grimwalde, A. (2004). HIV infection as a cofactor for severe falciparum malaria in adults living in region unstable malaria transmission in South Africa. AIDS 18(3): 547-554
Grimwlade, A.E., Lang, W. and Perkins, H. (2003). Childhood malaria in region of unstable transmission and Human Immunodeficiency virus prevalence. Pediatric infectious Journal. 22(12): 1057-1063.
Kalyesubala, M., Alger, et al., (2000). Effect of malaria infection in Human Immunodeficiency Virus type 1 infected Angula children. Pediatric infectious diseases Journal. 16(9): 876-881.
Kao, J.H., Chen, P.J., Lai, M.V. and Chon, D.S. (2001). Occult Hepatitis B Virus infection and clinical outcome of patients with chronic Hepatitis B. Journal of clinical Microbiology. 40: 4068.
Panicker, S., Girish Kumar, C.P., Selvaraj, V., Prabu, R. et al. (2021). Molecular epidomology of HBV among HIV infected individuals in Chennai, South India. Virus research. 300:198439.
Pessou, L.D., Gazzard, W., Huang, A.B. (2005). Entecavir in HIV/HBV co-infection patients: safety and efficacy in phase II study (ETV-038). Programs and abstract of 12th conference on Retro-virus and opportunistic infection: February 22-25; Boston Massachusetts.
Razza, G. Dorcacci, M., Pezzotti, P. and Philips, L.A. (2002). Co-infection of Hepatitis B with Human Immunodeficiency virus infected and progression to AIDS. Journal of infectious diseases. 172:1503-1508.
Robins, K.E. (2003). Human Immunodeficiency virus type 1 epidemic: date of origin, population history and characterization of early strain. Journal of Virology. 77:6359-6366.
Slustakes, L. and Marston, B. (2006). HIV and malaria when elephant collide. This conference on Retroviruses and opportunistic infection, Denver abstract 8.
Thio, C.L. and Locamini, S. (2007). Treatment of HIV/HBV co-infection: clinical and virologic issues. AIDS Rev. 9:40-53.
Thio, C.L., Seaberg, E.C., Skolasky, R.L. et al. (2002). HIV-1, hepatitis B virus, and risk of liver related mortality in the multi-center AIDS cohort study (MACS). Lancet. 360:1921-1926.
Thomas, P., Douglas, M., Mark, N. and Justin, S. (2006). Hepatitis cellular cancer in HIV- infection individuals. Expert Reviewed of Anticancer Therapy 6:11, 553.
Villet, S., Pichoud, C., Billioud, G. et al. (2008). Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 48:747-55.
WHO. (2006). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland, 2006.
Wyles, D. (2008). Hepatitis virus co infection in the Strategic Management of Antiretroviral Therapy (SMART) Study: A marker for nonliver, non-opportunistic disease mortality. Clin Infect Dis. 47:1476-8.

Most read articles by the same author(s)